DK0576478T4 - Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A - Google Patents

Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A

Info

Publication number: DK0576478T4
Authority: DK; Denmark
Prior art keywords: herpes simplex; monophosphoryl lipid; deacylated monophosphoryl; hsv glycoprotein; simplex vaccine
Prior art date: 1991-03-21

Application number

DK92906441T

Other languages

Danish (da)

English (en)

Other versions

DK0576478T3 (da

Inventor

Myriam Francotte

Jean-Paul Prieels

Moncef Slaoui

Nathalie Marie- Garcon-Johnson

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-21

Filing date

1992-03-17

Publication date

2001-07-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0576478(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-17 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1995-12-04 Publication of DK0576478T3 publication Critical patent/DK0576478T3/da

2001-07-23 Application granted granted Critical

2001-07-23 Publication of DK0576478T4 publication Critical patent/DK0576478T4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK92906441T 1991-03-21 1992-03-17 Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A DK0576478T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9105992A GB9105992D0 (en)	1991-03-21	1991-03-21	Vaccine
PCT/EP1992/000592 WO1992016231A1 (en)	1991-03-21	1992-03-17	HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (2)

Publication Number	Publication Date
DK0576478T3 DK0576478T3 (da)	1995-12-04
DK0576478T4 true DK0576478T4 (da)	2001-07-23

Family

ID=10691946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92906441T DK0576478T4 (da)	1991-03-21	1992-03-17	Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A

Country Status (33)

Country	Link
US (1)	US6027730A (de)
EP (1)	EP0576478B2 (de)
JP (1)	JP3530526B2 (de)
KR (1)	KR100224329B1 (de)
CN (2)	CN1058191C (de)
AP (1)	AP298A (de)
AT (1)	ATE129160T1 (de)
AU (1)	AU650521B2 (de)
BR (1)	BR9205745A (de)
CA (1)	CA2106492C (de)
CY (1)	CY1936A (de)
CZ (1)	CZ280505B6 (de)
DE (1)	DE69205566T3 (de)
DK (1)	DK0576478T4 (de)
ES (1)	ES2081102T5 (de)
FI (1)	FI107881B (de)
GB (1)	GB9105992D0 (de)
GR (1)	GR3017884T3 (de)
HU (1)	HU218025B (de)
IE (1)	IE69560B1 (de)
IL (1)	IL101290A (de)
MA (1)	MA22471A1 (de)
MX (1)	MX9201245A (de)
MY (1)	MY110086A (de)
NO (1)	NO307499B1 (de)
NZ (1)	NZ242057A (de)
PL (1)	PL170059B1 (de)
PT (1)	PT100262B (de)
SA (1)	SA92120459B1 (de)
SK (1)	SK279190B6 (de)
WO (1)	WO1992016231A1 (de)
YU (1)	YU28392A (de)
ZA (1)	ZA922011B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) *	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2156525A1 (en) *	1993-02-19	1994-09-01	Susan Dillon	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
JP4028593B2 (ja) *	1993-03-23	2007-12-26	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
FI955667L (fi) *	1993-05-25	1996-01-12	American Cyanamid Co	Adjuvantteja RS-viruksen vastaisia rokotteita varten
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
EP1298144A3 (de) *	1994-12-28	2006-05-31	University of Kentucky Research Foundation	Monoklonaler anti-idiotypischer Antikörper aus der Maus 3H1
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en)	1997-11-17	2002-03-12	University Of Kentucky Research Foundation	Methods and compositions for the treatment of psoriasis
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) *	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
SI1126876T1 (sl)	1998-10-16	2007-08-31	Glaxosmithkline Biolog Sa	Adjuvantni sistemi in vakcine
US7026155B2 (en)	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
EP1104767A1 (de)	1999-11-30	2001-06-06	Stichting Dienst Landbouwkundig Onderzoek	Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten
US9273326B2 (en)	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
EP2305294B1 (de)	2004-09-22	2015-04-01	GlaxoSmithKline Biologicals SA	Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
PT1861120T (pt)	2005-03-23	2016-08-18	Glaxosmithkline Biologicals Sa	Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
SI1962899T1 (sl)	2005-12-22	2011-11-30	Glaxosmithkline Biolog Sa	Pnevmokokna polisaharidna konjugatna vakcina
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
CA2647441C (en)	2006-03-30	2021-02-23	Glaxosmithkline Biologicals S.A.	Immunogenic composition comprising staphylococcus aureus saccharides
JP5639760B2 (ja)	2006-07-17	2014-12-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	インフルエンザワクチン
US20090181078A1 (en) *	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
DK2468300T3 (da)	2006-09-26	2018-01-29	Infectious Disease Res Inst	Vaccinesammensætning indeholdende syntetisk adjuvant
TW200908994A (en)	2007-04-20	2009-03-01	Glaxosmithkline Biolog Sa	Vaccine
PL2167121T3 (pl)	2007-06-26	2016-01-29	Glaxosmithkline Biologicals Sa	Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US8617564B2 (en)	2009-05-22	2013-12-31	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP5830015B2 (ja)	2009-06-05	2015-12-09	インフェクシャスディズィーズリサーチインスティチュート	合成グルコピラノシル脂質アジュバント
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
AU2010333749B2 (en) *	2009-12-21	2015-07-30	The Brigham And Women's Hospital, Inc.	Herpes simplex virus vaccines
WO2012074881A2 (en)	2010-11-24	2012-06-07	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN108126204A (zh) *	2011-03-11	2018-06-08	特斯通有限责任合伙公司	包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
EA027236B1 (ru)	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CA2845872C (en)	2011-08-22	2023-03-28	Nanobio Corporation	Herpes simplex virus nanoemulsion vaccine
CA2885693C (en)	2011-11-23	2020-07-28	Genocea Biosciences, Inc.	Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3388835B1 (de)	2012-05-16	2020-04-01	Immune Design Corp.	Impfstoffe gegen hsv-2
EP2941269B1 (de)	2013-01-07	2020-12-09	Mucosal Vaccine Technologies LLC	Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen
KR102039520B1 (ko)	2013-04-18	2019-11-01	이뮨 디자인 코포레이션	암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
EP3519427A4 (de)	2016-09-28	2020-03-11	Genocea Biosciences Inc.	Verfahren und zusammensetzungen zur behandlung von herpes
US11390650B2 (en)	2018-02-05	2022-07-19	The Brigham And Women's Hospital, Inc.	Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
AU2022208435A1 (en)	2021-01-18	2023-08-10	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372945A (en) *	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en) *	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US5149660A (en) *	1982-02-18	1992-09-22	University Patents, Inc.	Diagnostic reagents relating to herpes simplex virus
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
WO1988002634A1 (en) *	1986-10-20	1988-04-21	Chiron Corporation	Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen
ATE147633T1 (de) *	1988-10-27	1997-02-15	Univ Minnesota	Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US5597573A (en) *	1989-05-04	1997-01-28	Igen, Inc.	Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) *	1989-07-21	1992-10-27	Wisconsin Alumni Research Foundation	Method of stimulating the immune systems of animals and compositions useful therefor
JPH04506662A (ja) *	1989-07-14	1992-11-19	アメリカン・サイアナミド・カンパニー	接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
EP0560776B1 (de) *	1990-08-01	2000-02-09	Research Corporation Technologies, Inc.	Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
JP3005292B2 (ja) *	1990-08-02	2000-01-31	カイロンコーポレイション	単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US5196452A (en) *	1991-01-29	1993-03-23	Genelabs Incorporated	Macrocyclic anti-viral compound and method
US5166173A (en) *	1991-01-29	1992-11-24	Genelabs Incorporated	Method of treating herpes simplex virus infection
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2143716T3 (es) *	1992-06-25	2000-05-16	Smithkline Beecham Biolog	Composicion de vacuna que contiene adyuvantes.
CA2156525A1 (en) *	1993-02-19	1994-09-01	Susan Dillon	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
JP4028593B2 (ja) *	1993-03-23	2007-12-26	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
FI955667L (fi) *	1993-05-25	1996-01-12	American Cyanamid Co	Adjuvantteja RS-viruksen vastaisia rokotteita varten

1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
1992
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 CA CA 2106492 patent/CA2106492C/en not_active Expired - Lifetime
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/en active IP Right Grant
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/de not_active Expired - Lifetime
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active Expired - Lifetime
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0576478B2 (de)	2001-04-18
MX9201245A (es)	1992-10-01
IL101290A (en)	1996-07-23
AP9200368A0 (en)	1992-04-30
DK0576478T3 (da)	1995-12-04
DE69205566T2 (de)	1996-04-18
HU218025B (hu)	2000-05-28
PL170059B1 (pl)	1996-10-31
AU650521B2 (en)	1994-06-23
AP298A (en)	1994-01-14
CN1058191C (zh)	2000-11-08
CN1201692A (zh)	1998-12-16
NZ242057A (en)	1993-12-23
CN1101226C (zh)	2003-02-12
SA92120459B1 (ar)	2005-06-14
SK279190B6 (sk)	1998-07-08
DE69205566T3 (de)	2002-09-05
IE920881A1 (en)	1992-09-23
CA2106492A1 (en)	1992-09-22
NO307499B1 (no)	2000-04-17
ATE129160T1 (de)	1995-11-15
NO933343D0 (no)	1993-09-20
MY110086A (en)	1997-12-31
HU9302645D0 (en)	1994-01-28
CZ280505B6 (cs)	1996-02-14
FI934134L (fi)	1993-09-21
IE69560B1 (en)	1996-10-02
PT100262A (pt)	1993-06-30
ZA922011B (en)	1993-01-27
DE69205566D1 (en)	1995-11-23
BR9205745A (pt)	1994-10-18
ES2081102T3 (es)	1996-02-16
MA22471A1 (fr)	1992-10-01
WO1992016231A1 (en)	1992-10-01
ES2081102T5 (es)	2001-09-01
EP0576478A1 (de)	1994-01-05
JPH06505727A (ja)	1994-06-30
FI934134A0 (fi)	1993-09-21
GR3017884T3 (en)	1996-01-31
YU28392A (sh)	1994-11-15
AU1365792A (en)	1992-10-21
CA2106492C (en)	2003-12-09
US6027730A (en)	2000-02-22
HK1004525A1 (en)	1998-11-27
CN1065997A (zh)	1992-11-11
GB9105992D0 (en)	1991-05-08
EP0576478B1 (de)	1995-10-18
PT100262B (pt)	2001-05-31
IL101290A0 (en)	1992-11-15
NO933343L (no)	1993-09-20
SK94693A3 (en)	1994-05-11
CY1936A (en)	1992-03-17
KR100224329B1 (ko)	1999-10-15
HUT67052A (en)	1995-01-30
CZ195893A3 (en)	1994-07-13
FI107881B (fi)	2001-10-31
JP3530526B2 (ja)	2004-05-24

Publication	Publication Date	Title
DK0576478T4 (da)	2001-07-23	Herpes Simplex-vaccine omfattende HSV-glycoproteingD og 3-deacyleret monophosphoryl-lipid A
DK0689454T4 (da)	2005-05-30	Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
DK0633784T3 (da)	1997-01-20	Hepatitisvacciner indeholdende 3-O-diacyleret monophosphoryl-lipid A
CY2007016I1 (el)	2009-11-04	Εμβολιο ιου θηλωματος
FI943171L (fi)	1994-09-01	Ureaasipohjainen rokote Helicobacter-infektiota vastaan
LTIP335A (en)	1995-01-31	Vaccine for human immunodeficiency virus
FI944052A7 (fi)	1994-09-02	Oraalinen rokote
AP9100332A0 (en)	1992-01-31	Vaccines
EP0487909A3 (en)	1992-08-12	Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
EP0292293A3 (en)	1990-01-24	Newcastle disease virus vaccine and method for the applicaton thereof
NO922728D0 (no)	1992-07-10	Vaksine mot coccidiose
NO934106D0 (no)	1993-11-12	Liposome polysakkarid-vaksiner
HU9203976D0 (en)	1993-03-29	Vaccine based on modified herpes virus
EP0533263A3 (en)	1994-06-08	A multivalent hepatitis b virus vaccine
FI933060A7 (fi)	1994-01-04	Optisesti aktiiviset fenolijohdannaiset sekä niiden valmistus
GB9109763D0 (en)	1991-06-26	Herpes virus vaccine
GB9104903D0 (en)	1991-04-24	Viral vaccines
NO943251D0 (no)	1994-09-02	Oral vaksine
ID1028B (id)	1996-10-22	Vaksin
ZA918588B (en)	1992-08-26	Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
IL94510A0 (en)	1991-03-10	Influenza vaccine
GB9020799D0 (en)	1990-11-07	Viral vaccines
FI911504A7 (fi)	1992-09-28	Itsepalvelukassamenetelmä ja itsepalvelukassapöytä
NO923242D0 (no)	1992-08-19	Oral vaksine
GB9211075D0 (en)	1992-07-08	Vaccines against theileria annulata infection